The Transformative Nature of Psychedelics

The convergence of neurobiology and neuropsychology


Michael Murphy, MD, PhD | Erin M Griner PhD; Daniel Warthen PhD

How could the neuroplasticity process explain the therapeutic benefit of psychedelics, and what does it mean for clinical research? How can you use a fully integrated system of care to reduce the risks to the patient of engaging in a psychedelic trial? What do the current limitations of regulatory guidance on psychedelics in trials mean for their clinical development?

Find the answers to these questions and more on how to execute psychedelic trials:

Your form has been successfully submitted! Click the button below to access.
READ MORE
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE